

(<http://blog.pharmacist.com>)

[Home](#) > Sandoz receives FDA approval for adalimumab biosimilar

---

**Generic Name:**

Adalimumab-adaz

**Trade Name:**

Hyrimoz

**Company:**

Sandoz

**Notes:**

[Sandoz announced](#) FDA approval of adalimumab-adaz (Hyrimoz), a biosimilar to adalimumab (Humira), for treatment of rheumatoid arthritis, juvenile idiopathic arthritis in patients aged 4 years and older, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis, and plaque psoriasis.

The drug, a tumor necrosis factor inhibitor administered subcutaneously by injection, is the third FDA-approved biosimilar to adalimumab.

Approval was based on a randomized, double-blind, three-arm, parallel biosimilarity study that confirmed the pharmacokinetics, immunogenicity, and safety of adalimumab-adaz. The study met the primary endpoint, demonstrating bioequivalence for all primary pharmacokinetic parameters.

A confirmatory efficacy and safety biosimilarity study demonstrated therapeutic equivalence in the sensitive indication of patients with moderate to severe chronic plaque-type psoriasis, with a similar safety and immunogenicity profile to the reference biologic.

The most common adverse reactions (incidence > 10%) were infections (e.g., upper respiratory, sinusitis), injection-site reactions, headache, and rash.

**Medication Monitor Categories:**

[New Drug Approvals](#)

---

**Source URL:** <http://blog.pharmacist.com/new-drug-approvals/sandoz-receives-fda-approval-adalimumab-biosimilar>